Effect of Eplerenone on Novel Biomarkers of Mineralocorticoid Receptor Activation (ENOVA)
Status:
Not yet recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This blinded cross-over clinical trial will enroll participants with mild stage 1
hypertension to evaluate whether urinary extracellular transcript abundance predicts response
to an mineralocorticoid receptor (MR) antagonist, eplerenone.
Eligible participants will have a 2 week wash-in period followed by 4 weeks of treatment with
placebo or eplerenone. There will be a 2 week wash out period from study medications and then
participants will take the other drug (placebo or eplerenone) for 4 weeks. In addition,
participants will also provide urine and blood samples during the trial, have physical
assessments, and be monitored for safety.